Liang Yaping, Xu Xiaojia, Yin Mingjuan, Zhang Yan, Huang Lingfeng, Chen Ruoling, Ni Jindong
Department of Epidemiology and Biostatistics, Guangdong Medical University, Dongguan 523808, China.
Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen 518000, China.
Endocr J. 2019 Jan 28;66(1):51-63. doi: 10.1507/endocrj.EJ18-0109. Epub 2018 Nov 3.
We conducted a systematic review and meta-analysis to evaluate the effect of Berberine on glucose in patients with type 2 diabetes mellitus and identify potential factors may modifying the hypoglycemic effect. We searched PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, and Wanfang Database to identify randomized controlled trials that investigated the effect of Berberine. We calculated weighted mean differences (WMD) and 95% confidence interval (CI) for fasting plasma glucose (FPG), postprandial plasma glucose (PPG) and glycated haemoglobin (HbA1c) levels. Twenty-eight studies were identified for analysis, with a total of 2,313 type 2 diabetes mellitus (T2DM) patients. The pool data showed that Berberine treatment was associated with a better reduction on FPG (WMD = -0.54 mmol/L, 95% CI: -0.77 to -0.30), PPG (WMD = -0.94 mmol/L, 95% CI: -1.27 to -0.61), and HbA1c (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15) than control groups. Subgroup-analyses indicated that effects of Berberine on blood glucose became unremarkable as the treatment lasted more than 90 days, the daily dosage more than 2 g/d and patients aged more than 60 years. The efficiency of Berberine combined with hypoglycaemics is better than either Berberine or hypoglycaemic alone. The dosage and treatment duration of Berberine and patients' age may modify the effect.
我们进行了一项系统评价和荟萃分析,以评估黄连素对2型糖尿病患者血糖的影响,并确定可能影响其降糖效果的潜在因素。我们检索了PubMed、Embase、Cochrane图书馆、中国知网和万方数据库,以识别研究黄连素作用的随机对照试验。我们计算了空腹血糖(FPG)、餐后血糖(PPG)和糖化血红蛋白(HbA1c)水平的加权平均差(WMD)和95%置信区间(CI)。共纳入28项研究进行分析,涉及2313例2型糖尿病(T2DM)患者。汇总数据显示,与对照组相比,黄连素治疗能更有效地降低FPG(WMD=-0.54 mmol/L,95%CI:-0.77至-0.30)、PPG(WMD=-0.94 mmol/L,95%CI:-1.27至-0.61)和HbA1c(WMD=-0.54 mmol/L,95%CI:-0.93至-0.15)。亚组分析表明,随着治疗持续超过90天、每日剂量超过2 g/d以及患者年龄超过60岁,黄连素对血糖的影响变得不显著。黄连素联合降糖药的疗效优于单独使用黄连素或降糖药。黄连素的剂量、治疗持续时间以及患者年龄可能会影响其效果。